Cis-gnetin h and trans-gnetin h as therapeutic agents

Abstract

The cis-isomer and trans-isomers of the plant-derived compound gnetin H are shown have anticancer properties, anti-inflammatory properties, and low toxicity. Therapeutic and prophylactic compositions that contain cis-gnetin H, trans-gnetin H, an derivatives thereof, as well as methods of making and using said compositions, are provided, cis-gnetin H and/or trans-gnetin H can be used in purified form or as a plant extract.

1 . A method for treating or preventing a disease, disorder, or condition in a subject, the method comprising:
 administering to the subject a composition comprising an effective amount of at least one of cis-gnetin H, trans-gnetin H, or a derivative thereof;   wherein the disease, disorder, or condition is selected from the group consisting of a cancer, a precancerous condition, a tumor, an inflammation, an inflammatory disease, and an autoimmune disease.   
     
     
         2 . The method of  claim 1 , wherein the cancer is selected from bone cancer, brain cancer, breast cancer, cervical cancer, cancer of the larynx, lung cancer, pancreatic cancer, prostate cancer, skin cancer, cancer of the spine, stomach cancer, uterine cancer, or a blood cancer. 
     
     
         3 . The method of  claim 1 , wherein the cancer is a metastatic cancer. 
     
     
         4 . The method of  claim 1 , comprising administering the composition in an amount effective to inhibit or reverse the growth of a tumor in the subject. 
     
     
         5 . The method of  claim 4 , wherein the tumor comprises a solid tumor present in the bone, brain, breast, cervix, larynx, lung, pancreas, prostate, skin, spine, stomach, or uterus of the subject. 
     
     
         6 . The method of  claim 4 , wherein the tumor is a fast growing tumor. 
     
     
         7 . The method of  claim 1 , wherein the composition comprises an effective amount of cis-gnetin H. 
     
     
         8 . The method of  claim 1 , wherein the inflammatory disease or autoimmune disease comprises rheumatoid arthritis or an inflammatory bowel disease. 
     
     
         9 . The method of  claim 1 , wherein the subject is a domestic animal, a domesticated animal, a zoo animal, or human. 
     
     
         10 . (canceled) 
     
     
         11 . The method of  claim 1 , wherein the composition further comprised a pharmaceutically acceptable carrier. 
     
     
         12 . The method of  claim 1 , wherein the composition further comprises an additional active agent selected from the group consisting of an anticancer agent, antiangiogenic agent, a chemopreventive agent, an anti-inflammatory agent, a cytokine, a chemokine, a therapeutic antibody, an immunogen, an antigen, an adjuvant, or an antioxidant, an immunomodulatory compound, a biologic compound, an antineoplastic agent, and a chemotherapeutic agent. 
     
     
         13 . The method of  claim 12 , wherein the additional active agent is a non-naturally occurring compound. 
     
     
         14 . A pharmaceutical composition comprising:
 at least one of cis-gnetin H, trans-gnetin H, or a derivative thereof; and   a pharmaceutically acceptable carrier.   
     
     
         15 . The pharmaceutical composition of  claim 14 , comprising:
 a first active agent comprising at least one of cis-gnetin H, trans-gnetin H, or a derivative thereof; and   a second active agent comprising at least one compound selected from the group consisting of an anticancer agent, antiangiogenic agent, a chemopreventive agent, an anti-inflammatory agent, a cytokine, a chemokine, a therapeutic antibody, an immunogen, an antigen, an adjuvant, or an antioxidant, an immunomodulatory compound, a biologic compound, an antineoplastic agent, and a chemotherapeutic agent.   
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein the second active agent is a non-naturally occurring compound. 
     
     
         17 . The pharmaceutical composition of  claim 15  comprising at least one immunogen or antigen, wherein said composition is formulated for use as a vaccine. 
     
     
         18 . The pharmaceutical composition of  claim 17 , further comprising at least one adjuvant. 
     
     
         19 - 31 . (canceled) 
     
     
         32 . A kit comprising:
 at least one of cis-gnetin H, trans-gnetin H, or a derivative thereof;   a pharmaceutically acceptable carrier; and   instructions for use.   
     
     
         33 - 34 . (canceled) 
     
     
         35 . The kit of claim  34  further comprising one or more additional active agents selected from the group consisting of an immunogen, an antigen and an adjuvant. 
     
     
         36 . The kit of  claim 35 , wherein the additional active agent is a non-naturally occurring compound. 
     
     
         37 . (canceled)